Here we report on a novel MACC1-β-catenin-S100A4 axis and demonstrate that, based on this rationale, combined transcriptional inhibition of MACC1 and S100A4 restricts cancer cell motility and metastasis in CRC with seminal cross entity potential for cancer therapy. This evidence concerns the gene S100A4 and colorectal carcinoma.